Clinical Trial Update: Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intravenous and oral posaconazole (MK-5592) in children with invasive aspergillosis has completed, with results posted. The study MK-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• POSACONAZOLE (POSACONAZOLE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Invasive Aspergillosis | Phase 2 | Status: COMPLETED | Results posted: 2025-01-14